tiprankstipranks
Advertisement
Advertisement

AVIR Stock Latest News

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
The FlyAtea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
1M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026
PremiumCompany Announcements
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026
1M ago
AVIR
Is AVIR a Buy, Before Earnings?
PremiumPre-Earnings
Is AVIR a Buy, Before Earnings?
1M ago
AVIR
Atea Pharmaceuticals presents preclinical results of AT-587
PremiumThe Fly
Atea Pharmaceuticals presents preclinical results of AT-587
1M ago
AVIR
Atea Pharmaceuticals to highlight strategic priorities for FY26
PremiumThe Fly
Atea Pharmaceuticals to highlight strategic priorities for FY26
3M ago
AVIR
Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
PremiumThe FlyAtea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
4M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism
Premium
Company Announcements
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism
5M ago
AVIR
Atea Pharmaceuticals Advances Antiviral Programs with New Data
Premium
Company Announcements
Atea Pharmaceuticals Advances Antiviral Programs with New Data
5M ago
AVIR
AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
AVIR
Atea Pharmaceuticals announces presentation of data on BEM, RZR
PremiumThe Fly
Atea Pharmaceuticals announces presentation of data on BEM, RZR
5M ago
AVIR
Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?
PremiumCompany Announcements
Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?
5M ago
AVIR
Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir
PremiumCompany Announcements
Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir
5M ago
AVIR
Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors
PremiumCompany AnnouncementsAtea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors
5M ago
AVIR
Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination
Premium
The Fly
Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination
6M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress
Premium
Company Announcements
Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress
8M ago
AVIR
Atea Pharmaceuticals Advances in HCV Treatment Development
PremiumCompany Announcements
Atea Pharmaceuticals Advances in HCV Treatment Development
8M ago
AVIR
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
PremiumThe Fly
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
10M ago
AVIR
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
10M ago
8K
AVIR
Atea Pharmaceuticals Advances HCV Treatment Trials
PremiumCompany Announcements
Atea Pharmaceuticals Advances HCV Treatment Trials
11M ago
AVIR
AVIR Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsAVIR Upcoming Earnings Report: What to Expect?
11M ago
AVIR
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
Premium
The Fly
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
11M ago
AVIR
Atea Pharmaceuticals to host hepatitis C virus KOL panel
Premium
The Fly
Atea Pharmaceuticals to host hepatitis C virus KOL panel
11M ago
AVIR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >